BioCryst: Difference between revisions
Jump to navigation
Jump to search
m (BioCryst Pharmaceuticals Inc. moved to BioCryst: command decision to use the common name here.) |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:BioCryst logo.png|right|225px]] | |||
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical company based at 2190 [[Parkway Lake Drive]] in [[Birmingham]]. The company, which began in [[1986]], manufactures various types of perscription drugs. Its two most well-known products include a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208. | '''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical company based at 2190 [[Parkway Lake Drive]] in [[Birmingham]]. The company, which began in [[1986]], manufactures various types of perscription drugs. Its two most well-known products include a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208. | ||
The CEO and Chairman of the Board is Dr. [[Charles E. Bugg]], who was one of the companies co-founders in 1986. Set to retire in [[2007]], under Brugg's leadership, the company went public in [[1994]] seeing moderate profits. | The CEO and Chairman of the Board is Dr. [[Charles E. Bugg]], who was one of the companies co-founders in 1986. Set to retire in [[2007]], under Brugg's leadership, the company went public in [[1994]] seeing moderate profits. | ||
==Products== | |||
BioCryst is developing the following drug treatments: | |||
* Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb) | |||
* Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II) | |||
* Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II) | |||
* Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II) | |||
* BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I) | |||
* peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I) | |||
* BCX-4208 Oral, for treatment of Hepatitis C | |||
==References== | ==References== | ||
* [http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f16%2f0001206774-05-000364.html#FIS_BUSINESS BioCryst Pharmaceuticals Inc.] corporate | * BioCryst Pharmaceuticals, Inc. (2005) ''[http://www.biocryst.com/pdf/biocryst_2005_ar.pdf Corporate Report 2005]'' (PDF) - accessed September 21, 2006 | ||
* [http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f16%2f0001206774-05-000364.html#FIS_BUSINESS BioCryst Pharmaceuticals Inc.] corporate spotlight at NASDAQ. - Accessed September 21, 2006 | |||
* Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." ''Birmingham News''. | * Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." ''Birmingham News''. | ||
Revision as of 10:51, 21 September 2006
BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical company based at 2190 Parkway Lake Drive in Birmingham. The company, which began in 1986, manufactures various types of perscription drugs. Its two most well-known products include a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
The CEO and Chairman of the Board is Dr. Charles E. Bugg, who was one of the companies co-founders in 1986. Set to retire in 2007, under Brugg's leadership, the company went public in 1994 seeing moderate profits.
Products
BioCryst is developing the following drug treatments:
- Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
- Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
- Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
- Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
- BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
- peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
- BCX-4208 Oral, for treatment of Hepatitis C
References
- BioCryst Pharmaceuticals, Inc. (2005) Corporate Report 2005 (PDF) - accessed September 21, 2006
- BioCryst Pharmaceuticals Inc. corporate spotlight at NASDAQ. - Accessed September 21, 2006
- Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." Birmingham News.
External links
- BioCryst Pharmaceuticals Inc. website